China’s biotech boom: RAS-targeted drugs challenge US dominance
Bigger, fewer, tougher: the new era of China-US biotech partnerships
01:51 ETHengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
UBS Cuts TIGERMED TP to 52, Maintains Buy
STOCKS | Hong Kong's Innovative Drug Sector Declines
Manulife Singapore to offer multi-cancer blood test starting May